13 terminated. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 13 |
| Phase 2 | 2 | Terminated 2 |
Follow Uterine Fibroids: new trials by email Literature Review of Uterine Fibroids trials Research Report on Uterine Fibroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 103 | 2018-01-24 | 2022-06-30 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) Vilaprisan (BAY1002670), Placebo - Uterine Fibroids | Phase 3 | Terminated | Bayer | 93 | 2018-01-17 | 2023-05-03 |
| A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Vilaprisan (BAY1002670) - Uterine Fibroids | Phase 3 | Terminated | Bayer | 766 | 2017-07-31 | 2024-10-18 |
| Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Vilaprisan (BAY1002670), Standard of care - Uterine Fibroids | Phase 3 | Terminated | Bayer | 1272 | 2017-06-30 | 2025-07-28 |
| Ulipristal Acetate 10 mg and Asisted Reproduction Ulipristal Acetate, Placebo - Intramural Fibroids, Uterine Fibroids | Phase 3 | Terminated | Instituto Valenciano de Infertilidad, IVI VALENCIA | 2 | 2015-10-19 | 2020-10-14 |
| Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids MR-HIFU treatment, Sham treatment - Uterine Fibroids | Phase 2 / Phase 3 | Terminated | Philips Healthcare | 49 | 2012-05-01 | 2017-04-05 |
| Mifepristone to Treat Uterine Fibroids Oral administration of mifepristone 2.5 mg daily for three months, Oral administration of mifepristone 5 mg daily for three months - Uterine Fibroids | Phase 2 / Phase 3 | Terminated | Mediterranea Medica S. L. | 220 | 2010-03-01 | 2014-09-05 |
| Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids Proellex - Uterine Fibroids | Phase 3 | Terminated | Repros Therapeutics Inc. | 27 | 2009-04-01 | 2014-08-21 |
| Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids Proellex, placebo - Uterine Fibroids | Phase 3 | Terminated | Repros Therapeutics Inc. | 71 | 2009-02-01 | 2014-08-21 |
| Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids Proellex 25 mg, Proellex 50 mg, Placebo - Uterine Fibroids, Anemia | Phase 3 | Terminated | Repros Therapeutics Inc. | 8 | 2008-10-01 | 2014-08-21 |
| Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids Proellex 25 mg, Proellex 50 mg - Uterine Fibroids | Phase 3 | Terminated | Repros Therapeutics Inc. | 175 | 2008-10-01 | 2014-08-21 |
| Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids Proellex, Placebo - Uterine Fibroids | Phase 3 | Terminated | Repros Therapeutics Inc. | 77 | 2008-08-01 | 2014-08-21 |
| Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids Proellex 25 mg, Proellex 50 mg, Placebo - Uterine Fibroids, Anemia | Phase 3 | Terminated | Repros Therapeutics Inc. | 56 | 2008-06-01 | 2014-08-21 |
Leiomyoma (13) · Anemia (2) · Menorrhagia (2) · Myofibroma (1)
Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Connective and Soft Tissue (13) · Neoplasms, Muscle Tissue (13) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhage (2) · Menstruation Disturbances (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2)
telapristone acetate (6) · vilaprisan (4) · Sugars (2) · Standard of Care (1) · ulipristal acetate (1)
Repros Therapeutics Inc. (6) · Bayer (4) · Instituto Valenciano de Infertilidad, IVI VALENCIA (1) · Mediterranea Medica S. L. (1) · Philips Healthcare (1)
United States (9) · Czechia (4) · Bulgaria (2) · Canada (2) · China (2) · Finland (2) · Japan (2) · Mexico (2) · Norway (2) · Poland (2) · Russia (2) · South Africa (2) · South Korea (2) · Spain (2) · Australia (1)
Amanda Yunker, D.O. (1) · Andre van As, MD, PhD (1) · Aytekin Oto, MD (1) · Daniela Galliano, MDPhD (1) · Elizabeth David, MD (1) · Hyo Keun Lim, MD (1) · John H Fischer II, MD (1) · Peter Liu, M.D. (1) · Rajiv Chopra, PhD (1) · Robert K Zurawin, MD (1)
2016 (3), 2017 (1)